Compare STRIDES PHARMA SCIENCE with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ABBOTT INDIA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE ABBOTT INDIA STRIDES PHARMA SCIENCE/
ABBOTT INDIA
 
P/E (TTM) x 43.3 51.9 83.5% View Chart
P/BV x 2.0 16.8 12.1% View Chart
Dividend Yield % 0.2 0.4 58.6%  

Financials

 STRIDES PHARMA SCIENCE   ABBOTT INDIA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ABBOTT INDIA
Mar-19
STRIDES PHARMA SCIENCE/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,1478,834 13.0%   
Low Rs6425,458 11.8%   
Sales per share (Unadj.) Rs317.21,731.1 18.3%  
Earnings per share (Unadj.) Rs7.8211.9 3.7%  
Cash flow per share (Unadj.) Rs25.1219.9 11.4%  
Dividends per share (Unadj.) Rs2.0065.00 3.1%  
Dividend yield (eoy) %0.20.9 24.6%  
Book value per share (Unadj.) Rs274.3945.2 29.0%  
Shares outstanding (eoy) m89.5021.25 421.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.1 68.3%   
Avg P/E ratio x114.033.7 338.2%  
P/CF ratio (eoy) x35.732.5 109.9%  
Price / Book Value ratio x3.37.6 43.1%  
Dividend payout %25.530.7 83.1%   
Avg Mkt Cap Rs m80,058151,848 52.7%   
No. of employees `0002.53.5 71.9%   
Total wages/salary Rs m4,3414,356 99.6%   
Avg. sales/employee Rs Th11,325.810,555.5 107.3%   
Avg. wages/employee Rs Th1,731.41,249.9 138.5%   
Avg. net profit/employee Rs Th280.11,292.2 21.7%   
INCOME DATA
Net Sales Rs m28,39436,786 77.2%  
Other income Rs m9411,133 83.0%   
Total revenues Rs m29,33437,919 77.4%   
Gross profit Rs m3,9656,047 65.6%  
Depreciation Rs m1,540169 910.4%   
Interest Rs m1,96223 8,721.8%   
Profit before tax Rs m1,4036,989 20.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m972,485 3.9%   
Profit after tax Rs m7024,503 15.6%  
Gross profit margin %14.016.4 85.0%  
Effective tax rate %6.935.6 19.5%   
Net profit margin %2.512.2 20.2%  
BALANCE SHEET DATA
Current assets Rs m24,83627,610 90.0%   
Current liabilities Rs m18,9938,569 221.7%   
Net working cap to sales %20.651.8 39.8%  
Current ratio x1.33.2 40.6%  
Inventory Days Days7160 117.9%  
Debtors Days Days11327 413.9%  
Net fixed assets Rs m34,2891,057 3,244.3%   
Share capital Rs m895213 421.2%   
"Free" reserves Rs m23,65119,873 119.0%   
Net worth Rs m24,54620,086 122.2%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43729,409 222.5%  
Interest coverage x1.7311.6 0.6%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.41.3 34.7%   
Return on assets %4.115.4 26.5%  
Return on equity %2.922.4 12.8%  
Return on capital %6.934.9 19.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,697369 4,254.4%   
Fx outflow Rs m7354,918 15.0%   
Net fx Rs m14,962-4,549 -328.9%   
CASH FLOW
From Operations Rs m1,8714,991 37.5%  
From Investments Rs m5,826-2,570 -226.7%  
From Financial Activity Rs m-10,157-1,428 711.3%  
Net Cashflow Rs m-2,615993 -263.3%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 37.8 7.9 478.5%  
FIIs % 8.6 0.1 8,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 17.1 151.5%  
Shareholders   56,241 18,270 307.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   PROCTER & GAMBLE HEALTH  CIPLA  ASTRAZENECA PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 7, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - AUROBINDO PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS